We considered the longer-term post-trial clinical outcomes including CD4 count, hospitalisation, all-cause mortality, and incident tuberculosis for participants at the post-trial follow-up visits (Online Appendix 1, Table 6-A1). The gene discussed is CD4; the disease is tuberculosis.